MedTrace Logo

Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis

NCT02842021 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 283

Last updated 2020-11-18

No results posted yet for this study

Summary

To assess the efficacy and safety of a combination product S2G6T-1 compared to its monads and vehicle, applied twice daily for 7 days, in the treatment of symptomatic inflammatory interdigital tinea pedis in subjects 12 years of age and older. The results of this study will be utilized to perform power calculations for the Phase 3 pivotal trials.

Conditions

  • Tinea Pedis

Interventions

DRUG

S2G6T-1

Twice a day topical cream

DRUG

S2G6T-2

Twice a day topical cream

DRUG

S2G6T-3

Twice a day topical cream

DRUG

S2G6T-4

Twice a day topical cream

Sponsors & Collaborators

  • Sol-Gel Technologies, Ltd.

    lead INDUSTRY

Principal Investigators

  • Kathleen O Ashenfelter, MS · Cu-Tech, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-10-31
Completion
2017-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02842021 on ClinicalTrials.gov